...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Einstein (So Paulo) >Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases
【24h】

Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases

机译：通过诱导化疗，供体淋巴细胞输注，索拉非尼和阿扎胞苷的组合，成功地通过FLT3内部串联复制成功治疗了移植后复发的急性髓细胞白血病。 3例的报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Acute myeloid leukemia is a hematopoietic stem cell neoplastic disease associated with high morbidity and mortality. The presence of FLT3 internal tandem duplication mutations leads to high rates of relapse and decreased overall survival. Patients with FLT3 internal tandem duplication are normally treated with hematopoietic stem cell transplantation in first complete remission. Nevertheless, the incidence of post-transplant relapse is considerable in this group of patients, and the management of this clinical condition is challenging. The report describes the outcomes of patients with FLT3 internal tandem duplication positive acute myeloid leukemia who relapsed after allogeneic hematopoietic stem cell transplantation and were treated with the combination of re-induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Three cases are described and all patients achieved prolonged complete remission with the combined therapy. The combination of induction chemotherapy followed by donor lymphocyte infusion, and the maintenance with azacitidine and sorafenib can be effective approaches in the treatment of post-hematopoietic stem cell transplant and relapsed FLT3 internal tandem duplication positive acute myeloid leukemia patients. This strategy should be further explored in the context of clinical trials.
机译：急性髓细胞性白血病是与高发病率和高死亡率相关的造血干细胞肿瘤性疾病。 FLT3内部串联重复突变的存在导致较高的复发率并降低总生存期。具有FLT3内部串联重复的患者通常在首次完全缓解后接受造血干细胞移植治疗。然而，在这组患者中移植后复发的发生率是相当高的，并且这种临床状况的管理是具有挑战性的。该报告描述了异基因造血干细胞移植后复发并经再诱导化疗，供体淋巴细胞输注，索拉非尼和阿扎胞苷联合治疗的FLT3内部串联重复阳性急性髓性白血病患者的结局。描述了3例病例，所有患者均通过联合疗法获得了完全缓解。诱导化疗后再注入供体淋巴细胞，再加上阿扎胞苷和索拉非尼维持治疗，可能是治疗造血后干细胞移植和复发性FLT3内部串联重复阳性急性髓细胞白血病患者的有效方法。在临床试验中应进一步探索这种策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号